• Allergy to acalabrutinib • Pregnancy and breastfeeding • infection • Children below 18 years of age What is the dosage of Acalabrutinib? ... Skin: Rashes, bruises, ...

Skin : Rashes, bruises, ... acalabrutinib and should not be resumed at least 2 weeks after the last dose of acalabrutinib. • Patients are advised to report to the emergency center if serious ...

More than two-thirds (69%) of patients assigned acalabrutinib developed serious adverse reactions, the most common of which included pneumonia, COVID-19, pyrexia, second primary malignancy, rash ...

Acalabrutinib plus BR led to a 27% reduction in risk of death (HR, 0.73; 95% CI, 0.57-0.94; P = .016), as well as 34% PFS improvement over a median follow-up of 49.8 months vs the placebo group 1: ...

Whether fixed-duration acalabrutinib–venetoclax (with or without obinutuzumab) would result in better progression-free survival than chemoimmunotherapy in patients with untreated chronic ...

The most common adverse reactions (incidence at least 30%) for acalabrutinib are anemia, neutropenia, upper respiratory tract infection, thrombocytopenia, headache, diarrhea, and musculoskeletal pain.

Acalabrutinib, ibrutinib, ... Another cancer, such as skin cancer; ... This drug can also cause liver problems and allergic reactions, ...

WILMINGTON, Del., January 17, 2025--AstraZeneca’s CALQUENCE® (acalabrutinib) in combination with bendamustine and rituximab has been approved in the US for the treatment of adult patients with ...